The orally active and bioavailable ATR kinase inhibitor AZD6738 potentiates the anti-tumor effects of cisplatin to resolve ATM-deficient non-small cell lung cancer<i>in vivo</i>

Frank P. Vendetti(University of Pittsburgh), Christopher J. Bakkenist(UPMC Hillman Cancer Center)
Oncotarget
October 27, 2015
Cited by 240


Related Papers